Self-injection Device Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Self-injection Device Market is segmented By Product (Pen Injectors, Wearable Injectors, Needle-Free Injectors, Autoinjectors) By Usage (Disposable, Reusable) By Application (Autoimmune Disorder, Allergic Disorders, Hormonal Disease, Infectious Diseases, Other) By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Market Overview

The Global Self-injection Device market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Autoinjectors are a very useful class of medical devices that enable self-injection of drugs via the subcutaneous or intramuscular routes. They are equipped with prefilled syringes or cartridges and a spring mechanism that aids in the injection process. These devices have numerous advantages like easy self-administration, better patient compliance, reduced anxiety, and precise dosage delivery. Autoinjectors are used for both emergency and chronic conditions such as anaphylaxis, migraine, status epilepticus, psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Increasing Product Launches

The increasing product launches in the market are expected to boost the global market growth during the forecast period. For instance, in September 2022, Owen Mumford Pharmaceutical Services launched its latest Aidaptus auto-injector platform that has a patient-centric structure with automated needle insertion that delivers a straightforward and uniform user experience. Moreover, in October 2021, Ypsomed launched the globe’s foremost autoinjector with integrated connectivity. It links the SmartPilot, a networked reusable extension to the YpsoMate autoinjector for including the auto-injector into a digital therapy management technique.

Additionally, the rise in infectious and chronic diseases and growing research activities are among other factors that are expected to contribute to the global market growth during the forecast period.

Stringent Regulatory Authorities

Nevertheless, rigid regulations for authorization from regulatory heads and a lack of understanding of such devices in developing and underdeveloped countries have been hindering the growth of this market.

Segment Analysis

The global self-injection device  market is segmented based on product, application, distribution channel and region.

Pen Injector Product is Expected to Dominate Market

Owing to the increase in the pen injector approvals and introductions into the market the segment is estimated to dominate the global market during the forecast period. For instance, in November 2022, Tetris Pharma introduced Ogluo (glucagon prefilled autoinjector pen) for extreme hypoglycemia in children and adults with diabetes. 

Also, in May 2023 Boehringer Ingelheim obtained the U.S. Food and Drug Administration (FDA) has approval for its Cyltezo Pen, a unique autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-authorized Interchangeable biosimilar to Humira (adalimumab). Further, in September 2022, Terumo India, the Indian subsidiary of Terumo Corporation, a multinational leader in medical technology, launched the FineGlide, Sterile Pen Needle for individuals needing frequent insulin injections or other self-medication.

Geographical Analysis

North America is Expected to Dominate the Global Market

The North American market is expected to dominate the global autoinjectors market during the forecast period due to increasing market developments and product introductions. For example, in July 2023, Organon & Co. and Samsung Bioepis Co., Ltd. jointly introduced the HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) in the United States. 

The HADLIMA PushTouch Autoinjector has received the Arthritis Foundation's Ease of Use Certification, which recognizes developments that make life easier for those living with arthritis and other functional restrictions through lab and patient testing by the Intuitive Design Applied Research Institute (IDARI). 

Additionally, in July 2023, Fresenius Kabi introduced its citrate-free adalimumab biosimilar IDACIO (adalimumab-aacf) for the treatment of chronic autoimmune conditions for all suitable indications of the reference product, Humira (adalimumab) in the U.S. IDACIO is available in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector).

COVID-19 Impact Analysis

The high COVID-19 infection rate among the general population and overflow of hospitals with COVID-19 patients during peak time of COVID-19 pandemic had a negative side effect on patients with other life-threatening conditions such as anaphylaxis, as it resulted in patients hesitating to seek or delaying emergent medical care. Thus, the pandemic has led to decrease in the demand of the self-injection device, negatively impacting the global market.

Key Developments

• In September 2023, Ypsomed formed a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. 
• In October 2023, Enable Injections obtained FDA authorization for its enFuse injector for the delivery of Empaveli. Empaveli, commercialized by Apellis Pharmaceuticals, treats adults with paroxysmal nocturnal hemoglobinuria (PNH).

Competitive Landscape

The major global players in the market include Becton, Dickinson and Company, Ypsomed AG, Fresenius Kabi, Gerresheimer AG, Pfizer, Inc., Antares Pharma, Inc., West Pharmaceutical Services, Insulet Corporation, Owen Mumford Ltd. and SHL Group Auto.

Why Purchase the Report?

• To visualize the global self-injection device market segmentation based on product, usage, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of self-injection device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global self-injection device market report would provide approximately 69 tables, 69 figures and 190 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies